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ABSTRACT
Frontotemporal dementia is a devastating neurodegenerative disorder consisting of 
progressive focal atrophy of the prefrontal and temporal lobes. Emotional facial 
expression deficits are widely acknowledged in behavioural variant frontotemporal 
dementia (bvFTD) and are speculated to partially account for patients’ social-cognitive 
deficits. To our knowledge this is the first study to delineate the functional 
neuroanatomy of facial expression processing in bvFTD using functional MRI, while 
controlling for voxel-wise atrophy. The results indicate emotion-specific functional 
abnormalities in frontotemporal regions in patients with bvFTD. BvFTD patients also 
demonstrated decreased activity in posterior ventral visual regions, perhaps suggesting 
reduced input from anterior frontal and limbic regions. Finally, bvFTD was associated 
with increased activity in the dorsal attentional network, providing some of the first 
evidence of a potential compensatory response for functional deficits in frontotemporal 
regions. Together these findings suggest that functional MRI combined with tasks 
targeting social-cognitive deficits is a powerful technique to quantify neural systems 
involved in emotion processing in bvFTD.
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1.1 Frontotemporal dementia background
The increase in age and proportion of older persons has been coupled with an 
augmentation of age-related illnesses, specifically neurodegenerative diseases 
(Arvanitakis, 2010). In 1892, a neuropsychiatrist from Prague named Arnold Pick first 
described a patient presenting with progressive language and behavioural abnormalities 
while demonstrating definitive left temporal lobe atrophy post-mortem (Pick, 1892).
This marked the initial case of “Pick’s disease”. Soon after, Alois Alzheimer, a German 
psychiatrist and neuropathologist, discovered the presence of accumulated neuronal 
protein complexes in atrophied cortex (Alzheimer, 1911). He called his molecular 
finding “Pick’s bodies”, which later became associated with Pick’s disease. 
Accompanying our increased nosology of Pick’s disease over the last century has been a 
change in nomenclature to the now widely accepted “frontotemporal dementia” in order 
to better represent the heterogeneity in disease manifestation and progression. 
Frontotemporal dementia (FTD) is a devastating neurodegenerative disorder consisting of 
progressive, circumscribed focal atrophy of the prefrontal and temporal lobes (Lund- 
Manchester, 1994; Neary, 1998), resulting in striking personality and behaviour changes. 
FTD has been postulated to be the third most prevalent neurodegenerative dementia 
(behind Alzheimer’s disease and Lewy body disease) and the second most prevalent 
(behind Alzheimer’s disease) when disease onset precedes the age of 65 (Arvanitakis,
2010; Neary et al., 1998). Presently, there is no available cure for FTD, nor any 
symptomatic or modifying treatment demonstrating substantial efficacy.
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1.2 Clinical variants of frontotemporal lobar degeneration
Behavioural variant FTD (bvFTD) is the most common clinical subtype of 
frontotemporal lobar degeneration. Less common subtypes include semantic dementia 
and progressive non-fluent aphasia, which are both language-impairing clinical subtypes. 
Briefly, progressive non-fluent aphasia presents as a language expression deficit, 
resulting in effortful speech production despite adequate language understanding 
(Snowden et al., 1996). In comparison, semantic dementia features impairment of 
semantic knowledge relating to verbal and nonverbal concepts (Hodges et al., 1992; 
Kertesz et al., 2010; Snowden et al., 1996).
1.3 Clinical criteria of bvFTD
BvFTD is characterized by striking changes to social behaviour and personality 
relative to the pre-morbid state. The core diagnostic features of bvFTD according to the 
Neary Criteria, include an insidious onset and gradual disease progression, early deficits 
in interpersonal conduct, early behavioural dysrégulation, apathy, and loss of insight 
(Neary et al., 1998). Secondary clinical symptoms (not necessary for but may 
supplement diagnosis) include difficulty in modulating behaviour (e.g. stereotyped and 
perseverative behaviours, impulsiveness, mental inflexibility, inattentiveness, and 
utilization behaviours), inappropriate behaviours (e.g. hypersexuality, hyperorality, 
dietary alterations, and declining personal hygiene), and altered speech patterns (e.g.
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economy of speech, press of speech, stereotypy, echolalia, perseveration, and mutism; 
Neary et al., 1998). Despite abnormalities in social cognition and personality, bvFTD 
patients are relatively spared in language, memory, and visuospatial functioning (Graff- 
Radford and Woodruff, 2007; Kertesz, 2008; Lund-Manchester, 1994; Neary et al., 1998,
2005). In addition to meeting Neary Criteria, additional neuroimaging evidence (MRI, 
CT, or SPECT) must be present for bvFTD diagnosis, consistent with the new FTD 
consensus criteria (Rascovsky et al., 2010).
1.4 Heterogeneity in FTD phenotype
Instead of viewing the FTD subtypes as independent disease entities, research 
now supports an FTD syndrome theory with heterogeneous clinical and pathological 
symptomatology. Patients presenting with symptoms of one FTD clinical subtype can 
progress to develop symptoms of other subtypes (Arvanitakis, 2010; Graff-Radford and 
Woodruff, 2007; Kertesz et al., 2007; McKhann et al., 2001; Snowden et al., 2007), 
referred to as ‘secondary’ or even ‘tertiary syndromes’. Kertesz et al. (2007) followed 
319 FTD patients prospectively and determined that approximately two-thirds developed 
additional FTD syndromes. Similar behavioural and emotional symptoms frequently co­
occur in FTD patients who show semantic dementia symptoms (Hodges et al., 1992; 
Kertesz et al., 2007; Rosen et al., 2002a; Snowden et al., 1992), including severe 
difficulties in naming and word comprehension (predominantly nouns), empty 
spontaneous speech occurring in the presence of preserved speech fluency, syntax, and 
phonology (Hodges et al., 1992; Snowden et al., 1989,1992; Warrington, 1975). 
Semantic dementia has been referred to as the “What is...?” disease, due to the high




In general, the onset age of bvFTD has been estimated to be between 40 to 75 
years (Kertesz, 2008; Neary, 2005), with an average specific onset of about 59 years 
(Garcin et al., 2009). BvFTD has been estimated to have an earlier age of onset in 
comparison to other dementias, such as Alzheimer’s disease, which has an onset in the 
early 70’s (van der Flier, 2011). The average duration of the FTD disease course is about 
6.5-8.5 years, with a delay of approximately 3 years from symptom onset to diagnosis 
(Garcin et al., 2009), during which irreversible neuronal loss progresses. Population 
studies indicate a relatively equal distribution of FTD between sexes (Rosso et al., 2003; 
Snowden et al., 1996). FTD has been shown to be a heritable neurodegenerative disease, 
with up to 40% of FTD patients showing positive family history (Rohrer et al., 2009b).
1.6 Neuropathology
FTD is associated with the abnormal accumulation of neuronal proteins and 
neuronal loss, which likely begins decades prior to the initial manifestation of clinical 
symptoms (Finch et al., 2009; Rohrer et al., 2009a). This results in selective, but 
progressive, loss of brain function and tissue in the frontal and temporal lobes. The 
presenting clinical phenotype in frontotemporal lobar degeneration is hypothesized to be 
determined by the focalized frontotemporal neuronal atrophy patterns (Arvanitakis, 
2010). Neuropathological assessment and structural neuroimaging (CT or MRI) has
associated bvFTD symptomatology with circumscribed degeneration of the prefrontal 
and anterior temporal lobes, bilaterally, commonly right hemisphere greater than left 
(Boccardi et al., 2005; Davitzikos et al., 2008; Eslinger et al., 2007; McKhann et al., 
2001; Neary et al., 2005; Pereira et al., 2009; Perry and Miller, 2001; Rabinovici et al., 
2007; Rosen et al., 2002a; Short et al., 2005; Snowden et al., 2007; Varma et al., 2002). 
Specifically, early bvFTD atrophy is targeted to a frontal paralimbic network, including 
the anterior cingulate cortex, anterior insula, frontal pole, amygdala, and striatum, with 
frequent right hemisphere asymmetry (Seeley, 2008). In patients who develop semantic 
deficits in addition to behavioural and personality symptoms, atrophy is commonly 
observed bilaterally in the temporal poles, amygdala, ventromedial prefrontal cortex, 
insula, and inferoposterior temporal regions (Rosen et al., 2002a; Seeley et al., 2005). By 
assessing patterns of grey matter loss using voxel-based morphometry, the following four 
distinct anatomical subtypes have recently been proposed in bvFTD: temporal-dominant, 
temporofrontoparietal, frontotemporal, and frontal-dominant subtypes (Whitwell et al., 
2009).
1.7 Functional neuroimaging
Functional neuroimaging is commonly used as an adjunct in bvFTD diagnosis to 
index the integrity of the frontal and temporal lobes when clinical symptomatology is at 
an early stage and structural scans show mild (or no) atrophy (Foster et al., 2007; Graff- 
Radford and Woodruff, 2007; McNeill et al., 2007; Neary et al., 2005). Previous studies 
using PET or SPECT reported glucose hypometabolism and hypoperfusion, respectively, 
in prefrontal and/or anterior temporal lobes (Diehl-Schmid et al., 2007a; Graff-Radford
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and Woodruff, 2007; Hodges et al., 1992; Jeong et al., 2005; McKhann et al., 2001; 
McMurtray et al., 2006; McNeill et al., 2007; Mendez et al., 2006; Miller et al., 1997; 
Salmon et al., 2003; Talbot et al., 1998; Vanna et al., 2002). Functional magnetic 
resonance imaging (fMRI) has just recently been used to assess the functional 
connectivity of large-scale neural networks in neurodegenerative diseases. Resting-state 
fMRI has demonstrated that specific neurodegenerative diseases (e.g. bvFTD, 
Alzheimer’s disease, and semantic dementia) target individual large-scale neuronal 
networks (Seeley et al., 2009). More precisely, bvFTD shows reduced functional 
connectivity within an anterior ‘salience network’ (responsible for adaptive social- 
cognitive processes), composed of an anterior cingulate cortex and orbital ffontoinsula 
network. Interestingly, bvFTD shows increased connectivity within a posterior ‘default 
mode network’ (responsible for episodic memory and visuospatial functions), composed 
of a posterior hippocampal-cingulo-temporal-parietal network, regions actually 
vulnerable to atrophy in Alzheimer’s disease (Seeley et al., 2007; Zhou et al., 2010). It 
has been postulated that the clinical phenotypes associated with distinct 
neurodegenerative diseases are partly accounted for by functional changes within large- 
range neuronal networks (Seeley et al., 2010).
To our knowledge, the only previous FTD study to couple fMRI and a cognitive 
task investigated neuronal functioning associated specifically with working memory. 
FTD patients demonstrated decreased activation relative to Alzheimer’s patients within a 
working memory network, including frontal cortical regions (Rombouts et al., 2003). 
However, working memory impairment is not a direct cognitive symptom in bvFTD, and 
working memory problems are not a core feature of the disorder (Neary et al., 1998). No
study has yet combined functional neuroimaging and cognitive tasks targeting the core 
diagnostic social-cognitive deficits in bvFTD.
1.8 Face processing
1.8.1 Importance o f processing facial emotion
Facial expressions have long been recognized as a critical social cue for directing 
appropriate interpersonal behaviours (Darwin, 1872). The ability to successfully 
recognize emotion from faces in our environment is absolutely critical for social 
behaviour, especially empathic behaviour (Blair, 2003). Impairment in facial expression 
recognition, particularly expressions conveying negative valence such as fear and anger, 
is associated with inappropriate social behaviours (Blair and Cipolotti, 2000; Blair et al., 
2004; Corden et al., 2006; Marsh and Blair, 2008). In addition, accurate identification of 
fearful expressions can even predict prosocial behaviours (Marsh et al., 2007). One of 
the defining symptoms in bvFTD, independent of semantic impairment, is a lack of 
empathy for others, even immediate family members (Kertesz et al., 2000; Rankin et al.,
2006). A reduction in empathy in bvFTD patients is believed to be partially accounted 
for by impairments in facial expression processing (Diehl-Schmid et al., 2007b; Lough et 
al., 2006); however, neural substrates associated with emotional face processing have yet 
to be delineated in bvFTD.
1.8.2 Facial expression processing in FTD
Recognition of emotional faces has previously been shown to successfully 
differentiate mild bvFTD from healthy controls. Patients with mild bvFTD show deficits
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in both positive and negative facial emotion recognition (Diehl-Schmid et al., 2007b). 
Compared to mild Alzheimer’s disease patients, who performed at control levels, bvFTD 
patients showed a difficulty in recognizing negative emotions (Femandez-Duque and 
Black, 2005; Lavenu et al., 1999). Negative facial emotions are believed to be more 
difficult to recognize than positive ones (Russell, 1994), raising the issue of task 
difficulty potentially confounding patient performance. However, bvFTD patients have 
previously shown difficulty in recognizing both angry and fearful faces, the former 
understood to be easier to recognize than the latter (Femandez-Duque and Black, 2005). 
Despite definitive expression processing deficits, bvFTD patients have shown preserved 
general face processing abilities, such as facial identity discrimination (Rosen et al., 
2002b, 2004), facial familiarity judgment (Keane et al., 2002), and gender discrimination 
(Femandez-Duque and Black, 2005).
BvFTD patients with predominant frontal lobe atrophy show deficits in the 
recognition of both facial and vocal emotions, supporting a generalized emotion 
processing impairment independent of sensory modality (Keane et al., 2002). BvFTD 
patients with predominant temporal lobe atrophy are specifically vulnerable to emotion 
processing deficits as atrophy is commonly concentrated in the amygdala, anterior 
temporal lobes, and orbital frontal cortex, regions believed to play crucial roles in 
emotional stimulus processing (Rosen et al., 2002b). Temporal-dominant bvFTD 
patients have shown deficits in the processing of negative emotions, despite 
demonstrating preserved happy emotion processing (Rosen et al., 2002b). Comparisons 
between frontal-dominant and temporal-dominant bvFTD patients have demonstrated 
impaired negative expression processing in both subtypes; however, frontal-dominant
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bvFTD patients also showed difficulty processing happy faces, suggesting a more 
widespread facial expression processing deficit in this subtype (Rosen et al., 2004). It is 
important to note this finding remains controversial. For example another study reported 
preserved happy expression recognition processing in patients with frontal-dominant 
bvFTD (Lough et al., 2006).
1.8.3 Neural substrates o f facial expression processing
The neural architecture of face perception has been studied in both healthy and 
lesion populations. Utilizing fMRI, Kanwisher et al. (1997) demonstrated that the 
fusiform face area, located within the fusiform gyrus, shows enhanced activation to faces 
relative to common objects. Functional neuroimaging studies in humans have shown 
increased activation in ventral visual regions, specifically fusiform cortex, in response to 
emotional compared to neutral facial expressions (Amting et al., 2010; Fusar-Poli et al., 
2009; Morris et al., 1998; Pessoa and Ungerleider, 2004; Vuilleumier et al., 2001), and to 
faces depicting high relative to low emotional intensity (Surguladze et al., 2003). 
Research suggests that projections from the amygdala modulate activity in the ventral 
visual stream, enhancing neural representation in fusiform cortex for stimuli with 
emotional salience (Amaral et al., 1992; Vuilleumier et al., 2001, 2004). Patients with 
mesial temporal lobe sclerosis with both hippocampal and amygdala damage fail to show 
augmented fusiform activation in response to fearful faces; however, similar patients with 
sclerotic damage restricted to the hippocampus, sparing the amygdala, show increased 
fusiform activity during fearful face processing (Vuilleumier et al., 2004). In comparison 
to the amygdala, which processes crude, low resolution facial aspects, the fusiform
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activates most robustly to facial features in higher frequency resolution (Vuilleumier et 
al., 2003). The data are consistent with the idea that facial processing is associated with a 
spatially distributed neural network and emotion processing can modulate neural 
representation of faces in the ventral visual stream, specifically fusiform cortex.
In addition to outlining neurofunctional regions involved in face processing 
generally, specific neural regions have been associated with the healthy processing of 
individual facial expressions which are notably also regions affected by FTD pathology.
1.8.3.1 Angry faces
Functional neuroimaging studies have reported medial prefrontal/anterior 
cingulate cortex (Blair et al., 1999; Harmer et al., 2001), and ventrolateral prefrontal 
cortex (inferior frontal gyrus; Blair et al., 1999; Fusar-Poli et al., 2009) to be associated 
with angry expression processing. Angry faces signal to the observer the requirement of 
behaviour modification (Blair and Cipolotti, 2000; Blair et al., 1999; Mitchell, 2011), and 
ventrolateral prefrontal cortex appears to be active during this general process -  when an 
environmental cue signifies the modification of a behavioural response (as reviewed in 
Mitchell, 2011). In addition to processing facial expressions of anger, increased activity 
in ventrolateral prefrontal cortex has been associated with behaviour modification in 
response to social cues (Finger et al., 2006; Marsh et al., 2009).
1.8.3.2 Disgustedfaces
Defined as “bad taste”, Darwin acknowledged that disgust refers to repulsion- 
eliciting environmental stimuli (Darwin, 1872). FMRI has associated disgusted facial
expression processing with activation of the insula and basal ganglia (Fusar-Poli et al., 
2009; Kipps et al., 2007; Phillips et al., 1997; Sprengelmeyer et al., 1998). Interestingly, 
processing of vocal disgust expressions failed to elicit significant activation of these 
regions (Phillips et al., 1998). Insula activation in response to disgusted facial 
expressions may reflect the awareness of another’s gustatory processing (Jabbi et al.,
2007). Moreover, reduced sensitivity to disgust, measured by a disgust personality 
questionnaire, has been associated with decreased blood-oxygen-level dependent 
(BOLD) signal, measured via fMRI, in anteroventral insula upon viewing disgusting 
foods (Calder et al., 2007), demonstrating the association between insula functioning and 
disgust related sensitivity.
1.8.3.3 Fearful faces
Lesion studies have highlighted the amygdala as a central region involved in the 
processing of fearful expressions. Patients with bilateral amygdala injuries demonstrate 
impairment in recognizing negative facial emotions, most pronounced for fear (Adolphs 
et al., 1999). Functional neuroimaging studies, both PET and fMRI, have consistently 
demonstrated increased regional cerebral blood flow and increased BOLD signal, 
respectively, in the amygdala during fearful expression processing (Fusar-Poli et al., 
2009; Morris et al., 1996,1998,2002; Pesoa et al., 2002; Phillips et al., 1998). Previous 
work has reported a lesion patient with bilateral focal amygdala damage, demonstrating 
fear recognition deficits, who failed to fixate on the eye region during face recognition 
tasks; however, recognition was at control levels when explicitly directed towards the 
eyes (Adolphs et al., 2005). Amygdala activity has also been shown to predict an
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observer’s eye gaze shifts towards the eyes of a fearful face (Gamer and Buchel, 2009); 
thus, supporting the importance of eye regions when processing fearful faces (Adolphs,
2008) . This data also supports the role of the amygdala in directing attention towards 
salient features of environmental social cues, for example, during threatening stimuli 
evaluations. In addition to the amygdala, increased activation in the medial frontal gyrus 
has been associated with fearful expression processing (Fusar-Poli et al., 2009).
1.8.3.4 Happy faces
Previous neuroimaging studies have associated happy expression processing with 
increased activation in the amygdala (Fusar-Poli et al., 2009; Kipps et al., 2007; Pessoa et 
al., 2002) and rostral anterior cingulate/ventromedial prefrontal cortex (Fusar-Poli et al.,
2009) . Increased activity in ventromedial prefrontal cortex has also been associated with 
representing reward values of stimuli (as reviewed in Mitchell, 2011), such as pleasant 
tastes and smells (de Araujo et al., 2003; Gottfried et al., 2002; O’Doherty et al., 2001) 
and pleasant visual pictures (Dolcos et al., 2004). Difficulties recognizing happy 
expressions are not always reported following lesions to the amygdala and ventromedial 
prefrontal cortex (Lough et al., 2006; Rosen et al., 2002b), perhaps due to the ease with 
which these expressions can be identified.
1.8.3.5 Sad faces
Neural correlates implicated in the processing of sad expressions have been 
variable across studies. A previous PET study demonstrated hypermetabolism in the 
amygdala and temporal pole during sad expression processing (Blair et al., 1999). While
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viewing sad film excerpts, healthy females demonstrated activation in the anterior 
temporal pole, midbrain, amygdala, insula, and ventrolateral prefrontal cortex (Levesque 
et al., 2003). FMRI studies in healthy adults correlated the processing of sad expressions 
with increased amygdala activation (Fusar-Poli et al., 2009). The amygdala has been 
recognized to have a prominent role in emotional learning (LeDoux, 1998), where sad 
expressions represent unconditioned stimuli (Blair et al., 1999). Aversive conditioning to 
sad expressions is believed to be essential for healthy moral development (Blair, 1995). 
Further supporting the involvement of the amygdala in sad processing, a reduced 
autonomic responsiveness to sad expressions, compared to controls, has been reported in 
individuals with psychopathy, a disorder associated with amygdala dysfunction (Blair et 
al., 1997).
1.8.4 Neural correlates o f emotional face processing in FTD
The primary neural regions subject to atrophy in bvFTD parallel the regions 
previously implicated in the healthy processing of emotional facial expressions. As such, 
pathology in frontotemporal regions associated with emotion-specific facial expression 
processing can also partially account for bvFTD symptomatology. For example, 
ventrolateral prefrontal cortical atrophy, involved in angry expression processing, has 
also been correlated with inappropriate social behaviours in FTD (Massimo et al., 2009). 
FTD patients’ dysfunction in this neural region has been associated with deficits in 
modifying behaviour in response to task rules (Rahman et al., 1999), a likely partial 
explanation for abnormal social behaviours in FTD. Insula dysfunction in bvFTD may be 
related to the insensitivity towards disgusting social cues (e.g. disgusted faces) and
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disgust-inducing environmental stimuli (e.g. rotten food; Ikeda et al., 2002). Anterior 
temporal cortex, specifically the amygdala, and medial frontal regions have not only been 
previously implicated in the processing of fearful, happy, and sad faces, but also 
considered to be involved in experiencing empathic behaviours towards stressful or upset 
individuals (as reviewed in Decety and Jackson, 2004). Previous studies have correlated 
a lack of empathy in bvFTD to structural atrophy in anterior temporal and medial frontal 
cortex (Decety and Jackson, 2004; Eslinger et al., 2011; Kipps and Hodges, 2006).
Prior studies of the neural correlates of facial expression processing in FTD 
focused exclusively on atrophy correlations, with limited results. For example, negative 
expression recognition deficits in frontotemporal lobar degeneration have been correlated 
with right inferolateral temporal cortex atrophy (Rosen et al., 2006) and angry faces with 
posterior insula (Omar et al., 2010). Structural atrophy and facial expression recognition 
correlations appear insensitive in dissociating frontal-dominant and temporal-dominant 
FTD patients (Omar et al., 2010).
1.9 Thesis hypotheses
Despite the established behavioural impairment in recognizing facial expressions, 
the functional neuroanatomy of facial expression processing has yet to be delineated in 
bvFTD. We have applied fMRI, while correcting for measurable atrophy, to index the 
functional neural correlates in bvFTD patients during the processing of emotional facial 
expressions. We hypothesized bvFTD patients would demonstrate decreased BOLD 
signal in frontotemporal regions that are both directly affected by FTD pathology and 
essential for facial expression processing. Specifically, we predicted bvFTD patients
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would demonstrate decreased activation relative to controls in ventrolateral prefrontal 
cortex (inferior frontal gyrus) when processing angry expressions, in the amygdala during 
fearful expressions, and in the insula during disgusted expressions. Next, we predicted 
fMRI will demonstrate functional differences between bvFTD patients without semantic 
deficits and those with semantic deficits; specifically, bvFTD patients without semantic 
deficits would show reduced frontal activation during angry and disgusted faces and 
bvFTD patients with semantic deficits would demonstrate reduced activation in anterior 
temporal lobe regions, such as the amygdala, during the processing of fearful, happy, and 
sad expressions. In addition, due to functional abnormalities in limbic regions, we 
hypothesized bvFTD patients would show secondary reduction in BOLD signal in 
regions downstream from limbic system structures and not typically affected in FTD, but 
perform a fundamental role in general face processing, such as fusiform cortex. Lastly, 
detected neural dysfunction was predicted to survive voxel-wise grey matter atrophy 
correction, providing support for the notion that anomalous changes in neural function 
may precede atrophy in FTD.
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CHAPTER 2
Elucidating the Functional Neural Correlates of Emotional Face Processing Deficits 
in Behavioural Variant Frontotemporal Dementia
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2.1 Introduction
Frontotemporal dementia (FTD) is a neurodegenerative disorder characterized by 
progressive dysfunction in social behaviour typically beginning in mid-life (50s-60s). 
FTD is associated with abnormal accumulation of neuronal proteins and neuronal loss, 
which likely begins decades before the first manifestation of clinical symptoms (Finch et 
al., 2009; Rohrer et al., 2009). This leads to selective, but progressive, loss of brain 
function and tissue in regions of the frontal and/or temporal lobes. The core clinical 
diagnostic features of behavioural variant FTD (bvFTD), the most common clinical 
subtype of frontotemporal lobar degeneration, include an insidious onset and gradual 
disease progression, early deficits in interpersonal conduct, early behavioural 
dysregulation, apathy, and loss of insight (Lund-Manchester, 1994; McKhann et al., 
2001; Neary et al., 1998). Similar behavioural and emotional symptoms frequently co­
occur in FTD patients who show semantic deficits (Hodges et al., 1992; Kertesz et al., 
2007; Rosen et al., 2002a; Snowden et al., 1992). One of the hallmark symptoms of 
bvFTD, irrespective of semantic impairment, is a loss of empathy for others. This 
symptom is thought to be partially accounted for by a reduction in human emotion 
recognition (Diehl-Schmid et al., 2007; Lough et al., 2006; Rankin et al., 2005). While a 
growing body of research has associated regions of atrophy with bvFTD clinical 
symptoms (Eslinger et al., 2011; Huey et al., 2009; Massimo et al., 2009; Woolley et al., 
2007), the functional neural correlates of the core emotion processing deficits in bvFTD 
have yet to be examined.
Facial expressions are one way in which we communicate emotional information 
critical for successful social behaviour (Blair, 2003; Darwin, 1872). Deficient facial
32
expression recognition, particularly recognition of negative expressions such as fear and 
anger, is associated with inappropriate social behaviours (Blair and Cipolotti, 2000; Blair 
et al., 2004; Corden et al., 2006; Marsh and Blair, 2008). Previous studies have 
demonstrated that patients with bvFTD show deficits in facial expression recognition, 
while general face processing abilities such as facial identity discrimination (Rosen et al., 
2002b, 2004), facial familiarity judgment (Keane et al., 2002), and gender discrimination 
(Femandez-Duque and Black, 2005) are comparatively preserved. Patients with mild 
bvFTD show impaired positive and negative facial emotion processing relative to healthy 
controls (Diehl-Schmid et al., 2007), and impaired negative expression recognition 
relative to patients with mild Alzheimer’s disease (Femandez-Duque and Black, 2005; 
Lavenu et al., 1999). Abnormalities in the recognition of negative emotional expressions 
have been noted both in patients with bvFTD with frontal-dominant (Keane et al., 2002; 
Lough et al., 2006) and temporal-dominant atrophy (Rosen et al., 2002b). However, 
evidence exists that emotional social-cognitive deficits may be more pronounced in the 
frontal subtype. Direct comparison of bvFTD patients with frontal versus temporal 
predominant atrophy demonstrates that while both groups were impaired on negative 
emotions, frontal-dominant type patients showed additional deficits recognizing happy 
facial expressions (Rosen et al., 2004).
The neural regions supporting facial expression processing in healthy adults show 
great overlap with the neural regions affected early in the course of bvFTD. In the early 
stages of bvFTD, atrophy is predominant in a frontal paralimbic network, including the 
anterior cingulate cortex, anterior insula, frontal pole, amygdala, and striatum, with 
frequent right hemisphere predominance (Rosen et al., 2002a; Seeley et al., 2008). In
patients who develop semantic deficits in addition to behavioural and personality 
symptoms, atrophy is commonly observed bilaterally in the temporal poles, amygdala, 
ventromedial prefrontal cortex, insula, and inferoposterior temporal regions (Rosen et al., 
2002a; Seeley et al., 2005). A number of lesion and functional neuroimaging studies 
have delineated the neural regions associated with healthy facial expression processing. 
Regions of the temporal-occipital cortex, namely the fusiform gyrus, are robustly 
activated when viewing faces and processing basic facial features (Haxby et al., 2000; 
Kanwisher et al., 1997; Winston et al., 2004). Activity in this region is augmented for 
emotional relative to neutral expressions (Fusar-Poli et al., 2009; Morris et al., 1998; 
Vuilleumier et al., 2001). Emotional faces also activate frontotemporal limbic regions, 
with some unique emotion-specific patterns. The amygdala is typically active when 
fearful, sad or happy faces are viewed (Adolphs et al., 1994; Fusar-Poli et al., 2009; 
Pessoa et al., 2002; Whalen et al., 1998). Rostral anterior cingulate/ventromedial 
prefrontal cortex activity is greatest during happy and fearful faces (Fusar-Poli et al., 
2009). In contrast, the anterior insula and ventrolateral prefrontal cortex are activated by 
disgusted and angry facial expressions, respectively (Blair et al., 1999; Fusar-Poli et al., 
2009; Phillips et al., 1997).
Despite the body of data supporting facial expression recognition deficits in 
bvFTD, the functional neuroanatomy of facial expression processing has yet to be 
examined and delineated in this disease. Functional magnetic resonance imaging (fMRI) 
combined with targeted cognitive tasks offers a potentially powerful technique to detect 
neural dysfunction directly related to symptomatology associated with a 
neurodegenerative disease p r io r  to detectable atrophy (Dickerson et al., 2005). In the
present study we used fMRI while correcting for voxel-wise atrophy across the brain to 
index the functional brain activity during implicit emotional facial expression processing 
in bvFTD patients and matched controls. We hypothesized that patients with bvFTD 
would show decreased blood-oxygen-level dependent (BOLD) signal, following 
measurable atrophy correction, in frontotemporal regions that are both directly affected 
by bvFTD pathology and critical for facial expression processing. Specifically, we 
predicted that bvFTD patients would show reduced BOLD signal compared to controls in 
ventrolateral prefrontal cortex (inferior frontal gyrus) and anterior insula while viewing 
angry expressions, in the amygdala during fearful expressions, and in the insula during 
disgusted expressions. Second, we predicted that direct comparisons between bvFTD 
patients without semantic dementia symptoms and those with semantic dementia 
symptoms would reveal functional group differences, showing reduced frontal activation 
during angry, fearful, happy, and sad expressions in bvFTD patients without semantic 
deficits and reduced activation in anterior temporal regions such as the amygdala during 
fearful, happy, and sad expressions in patients with semantic impairments. Third, due to 
functional abnormalities in limbic regions, we predicted that bvFTD patients would show 
indirect reductions in BOLD signal in posterior downstream targets of the limbic system 
that are typically unaffected in bvFTD, but perform a more general role in face 
processing, such as fusiform cortex. We predicted that functional abnormalities 
following all group contrasts would be present even after a whole brain voxel-wise grey 
matter correction for atrophy/volume differences, thus representing a critical target in the 





Following a complete description of the study, all participants (or their surrogates) 
provided written informed consent. The procedures were approved by the Health 
Sciences Research Ethics Board at the University of Western Ontario. Patients were 
recruited through the Cognitive Neurology and Alzheimer Research Centre (CNARC) at 
St. Joseph’s Hospital in London, Ontario, Canada. Healthy controls were recruited 
through the local FTD caregiver support group and the CNARC volunteer pool. Patients 
included in the study met Neary Criteria for bvFTD (Neary et al., 1998) and had 
supportive neuroimaging (MRI, CT, or SPECT; see Figure 2.1 for MRI pictures of 
example bvFTD patients included in the study). Study exclusion criteria included any 
history of traumatic brain injury or other neurological or psychiatric disorder apart from 
bvFTD. In total, 24 bvFTD patients and 18 healthy controls were initially enrolled. 
Twenty patients with bvFTD successfully completed the fMRI scan. Four patients were 
unable to complete the fMRI scan (secondary to claustrophobia or excessive movement). 
BvFTD patients were further subcategorized according to the presence (n = 8) or absence 
(n = 12) of semantic dementia symptoms (Hodges et al., 1992; Snowden et al., 1989; 
Warrington, 1975), and were matched as closely as possible to healthy controls in age, 
gender, handedness, and education (Table 2.1; see Appendix A for subjects’ medical 
history).
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Figure 2.1. MRI pictures of bvFTD patients included in the present study (left side = 
right hemisphere; coronal slices). (A) 71 year old female bvFTD patient with semantic 
deficits, approximately 4.5 years post symptoms onset, demonstrating predominantly 
temporal lobe atrophy, left greater than right. (B) 61 year old male bvFTD patient 
without semantic deficits, approximately 7 years post symptoms onset, demonstrating 
predominantly frontal lobe atrophy.
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Table 2.1. Subject demographic and neuropsychological characteristics
H e a lth y  co n tro ls b v F T D  w ith o u t SD b v F T D  w ith  SD
A ge, y e a rs 6 2 .4  (1 0 .8 ) 62 .8  (9 .2 ) 69.1 (3 .8 )
M :F , n 13:5 10:2 5:3
H an d ed n ess  R :L , n 16:2 10:1* 8:0
E d u ca tio n , y ea rs 15.8  (5 .0 )** 11.3 (3 .2 ) 1 1 .4 (2 .9 )
I lln ess  d u ra tio n , y ea rs N A 5.3 (4 .0 ) 5 .5 (2 .2 )
M M S E 2 8 .7 (1 .8 ) 2 2 .5  (6 .5 ) 17.4 (6 .9 )
F B I N A 3 4 .0 (1 1 .9 ) 39 .6  (8 .8 )
Im m ed ia te  p ro se  reca ll 10.8 (3 .2 ) 4 .3  (4 .1 ) 1.3 (1 .6 )
D e la y e d  p ro se  reca ll 9 .7  (3 .8 ) 3 .2  (3 .7 ) 0 .6  (1 .0 )
L e tte r  flu en cy 3 6 .7 (1 1 .7 ) 19 .6  (12 .9 ) 9 .4  (6 .9 )
S em an tic  flu en cy 17.8 (4 .4 ) 11.1 (5 .9 ) 4 .2  (5 .8 )
O b je c t n am in g 2 0 .0  (0 .0 ) 18.0  (3 .4 ) 12.0 (4 .6 )
S p o n tan eo u s  c lo c k  d ra w in g 9 .13  (0 .7 ) 7 .9  (2 .6 ) 7 .7  (2 .5 )
C lo ck  c o p y in g 9 .7  (0 .5 ) 8 .0  (2 .6 ) 9 .0  (0 .0 )
B eck  D e p re ss io n  In v e n to ry 6 .8  (4 .3 ) 10.2  (8 .2 ) N A
T ra ils  A 3 8 .6 (1 1 .1 ) 4 2 .7 (1 5 .4 ) 78 .6  (3 7 .1 )
T ra ils  B 102.5  (5 5 .0 ) 88 .0  (38 .0 ) 91 .0  (N A )
A N A R T 13.4  (8 .9 ) 3 0 .6  (8 .8 ) 38.5  (6 .6 )
W C S T 5.5  (0 .9 ) 2 .6  (2 .2 ) 3 .5 (2 .4 )
S troop  A 9 1 .5  (16 .0 ) 6 1 .5 (2 7 .4 ) 38 .7  (2 4 .1 )
S troop  B 6 3 .4  (14 .0 ) 39.1 (2 4 .8 ) 25 .5  (2 9 .0 )
S troop  C 3 5 .0  (7 .6 ) 19.5 (1 6 .3 ) 8 .0  (9 .9 )
Values represent mean (standard deviation). Not all patients completed all neuropsychological tests. SD = semantic 
deficits. * One bvFTD without semantic deficits patient was ambidextrous. ** Healthy controls > bvFTD without SD = 
bvFTD with SD, p  < .05. See Appendix B for neuropsychological tests sample sizes and Appendix C for descriptions 
of neuropsychological tests.
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2.2.2 fM R l task
Participants were presented with photographs of angry, disgusted, fearful, happy, 
and sad emotional facial expressions from the Karolinska Directed Emotional Faces, a 
cross-culturally validated stimulus set (Lundqvist et al., 1998). The facial stimuli were 
cropped to remove hair and neck regions, eliminating extraneous features. Emotional 
expressions were morphed with neutral facial expressions from the same actors using 
Abrosofit FantaMorph (Abrosofit, Beijing, Version 4) software to create two levels of 
emotional intensity (40% and 100% intensity). A total o f 160 different faces were 
available for random selection for each run of the paradigm. The stimuli were projected 
onto a screen that could be viewed by the subject via a positioned mirror above the MRI 
scanner head-coil. Following previous studies (Blair et al., 1999; Marsh et al., 2008; 
Phillips et al., 1998), participants were required to indicate the gender of the faces by 
making a button press response while viewing the faces in the scanner. Stimuli were 
presented in a rapid event-related manner using E-prime software (Schneider et al., 
2002). Subjects completed 3 independent runs of the task. Each run was composed of 
104 randomly occurring trials: 80 emotional faces presented for 2.5 seconds followed by 
a fixation cross for 0.5 seconds, and 24 interspersed “jittered” trials consisting of a 
fixation cross presented for 3 seconds (Figure 2.2). Each run lasted 5 minutes and 42 
seconds. Practice trials outside of the scanner were carried out for both participant 











Figure 2.2. Trial schematic depicting the time-course for two consecutive trials. The first 
face shows a disgusted male at 40% emotional intensity and the second face shows a 
100% fearful female.
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2 .2 .3  Im a g e  a cq u is itio n
Data was acquired using a 3-Tesla Siemens Tim Trio MRI scanner with a 32 
channel head-coil. Functional data was acquired using T2*-gradient echo-planar imaging 
sequence (45 contiguous slices of 2 x 2mm in plane; slice thickness = 2.5mm; repetition 
time = 3000ms; echo time = 30ms; field of view = 24cm; 120 x 120 matrix). This 
sequence generated a voxel resolution of 2 x 2 x 2.5mm. Following the final task run, a 
high resolution structural Ti-weighted acquisition of the complete brain volume was 
obtained in the axial plane (repetition time = 2300ms; echo time = 4.25ms; field of view 
= 25.6cm; 192 slices; voxel size = 1mm3; 256 x 256 matrix).
2 .2 .4  Im a g e  p r o c e s s in g  a n d  an a lysis:
2 .2 .4 .1  S tru c tu ra l im a g in g
To account for grey matter volume differences influencing the fMRI signal, 
volumetric brain analysis was carried out. Atrophy and volume differences were 
corrected for by including a covariate into the fMRI analysis reflecting subjects’ voxel- 
wise grey matter tissue probabilities. Ti-weighted MRI images were analyzed using FSL 
tools (Smith et al., 2004; www.finrib.ox.ac.uk/fsl). Initially, structural images were 
brain-extracted using BET (Smith, 2002). Second, tissue was segmented into GM, WM, 
and CSF using FAST4 (Zhang et al., 2001). The resulting grey matter volume images 
were aligned to the MNI152 template using the affine registration tool FLIRT (Jenkinson 
et al., 2002; Jenkinson and Smith, 2001), and smoothed with an isotropic Gaussian kernel 
with a sigma of 4mm (~9mm FWHM). Prior to fMRI analysis, grey matter probability 
maps were realigned to Talaraich standard space.
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2 .2 .4 .2  F u n ctio n a l im a g in g
The fMRI data were preprocessed and analyzed using Analysis of Functional 
Neuroimages (AFNI; Cox, 1996) software package. The first five volumes of each run 
were discarded to ensure magnetization equilibrium. Motion correction was 
accomplished by registering all BOLD data of each run to the last volume of the last run, 
immediately preceding the anatomical scan. Subjects’ functional data were spatially 
smoothed with a 4mm isotropic Gaussian kernel (~9mm FWHM). The time series data 
were normalized by dividing the signal intensity of a voxel at each time point by the 
mean signal intensity of that voxel for each run and multiplying the result by 100. 
Resultant regression coefficients represented the percent signal change relative to the 
mean. Regressors were created to represent trials when a response was made for each 
emotion/intensity by convolving the stimulus events with a gamma-variate basis function 
to account for the slow hemodynamic response. A baseline plus linear drift and quadratic 
trend were modeled to the time series of each voxel to correct for voxel-wise correlated 
drifting, producing a beta coefficient and /-statistic for each voxel and regressor.
Subjects’ anatomical scans were registered to Talaraich standard space, allowing each 
subject’s functional data to be aligned to their own normalized anatomical template for 
group analysis.
Subjects’ regressors for 40% and 100% emotional intensity were initially 
averaged within emotions [e.g. (Angry-40% + Angry-100%)/2] to increase statistical 
power. Planned voxel-wise /-tests, covaried for voxel-wise grey matter, were performed 
to determine whether emotion-specific group differences in BOLD activation persisted
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when correlations between grey matter volume and activation were controlled for. To 
elucidate changes in activation patterns in response to emotional faces, the following two 
comparisons were examined: all bvFTD patients versus healthy controls, and bvFTD 
patients without semantic deficits versus bvFTD patients with semantic deficits. Whole 
brain contrasts were thresholded at ¿><0.005 and corrected for multiple comparisons to 
p<0.05 using AFNI’s 3dClustSim spatial clustering program with 10, 000 Monte Carlo 
simulations on a whole brain EPI matrix. This operation estimates the probability of 
random noise producing a cluster of a given size, based on a specified uncorrected voxel- 
wise threshold. The above whole brain contrast yielded significant corrected clusters 
with a minimum volume of 270mm3. The one exception was the amygdala, which was 
thresholded at¿><0.05 (small-volume corrected with a significant cluster at a minimum 
volume of 430mm ), because of a  p r io r i  predictions concerning this structure’s 
involvement in face processing.
2.3 Results
2 .3 .1  B eh a v io u ra l d a ta
All subjects made successful gender discriminations for the majority of trials 
(Table 2.2). Healthy controls performed the gender discrimination at higher accuracy 
than bvFTD patients { d f -  36,/?<0.05 for between group emotion contrasts). It was 
observed that bvFTD patients were often inconsistent with the response buttons used for 
male versus female. Thus, we evaluated gender discrimination data that was available on 
12 of the 20 bvFTD patients from an independent study using the same facial stimuli, 
where patients verbally indicated the gender. When responses were reported verbally,
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performance improved (M= 88.54%, S D  =  9.82%) relative to the button press gender 
discrimination task in the present study. Although bvFTD patients responded to 
significantly less trials than controls (Table 2.2), patients’ overall response frequency 
remained high (M =  85.2%, S D  -  15.0%).
Table 2.2. Comparison between bvFTD patients and healthy controls on gender 
discrimination accuracy and response frequency
H e a lth y  co n tro ls b v F T D
G e n d e r  d iscr im in a tio n  
a c c u r a c y 1 *
A n g ry 91.1 (6 .4 ) 7 5 .7 (1 8 .0 )
D isg u s t 9 3 .4  (5 .4 ) 77.3  (19 .9 )
F e a r 93 .2  (3 .7 ) 76 .7  (20 .7 )
H ap p y 9 2 .0  (2 .6 ) 7 6 .2 (2 1 .9 )
S ad 93 .7  (3 .8 ) 77.1 (20 .9 )
R e sp o n se  freq u en cy
A n g ry 9 7 .9  (2 .7 ) 8 5 .0 (1 4 .9 )
D isg u s t 9 8 .4  (2 .4 ) 8 4 .4 (1 6 .1 )
F e a r 9 9 .2 (1 .5 ) 84 .8  (16 .5 )
H a p p y 98 .5  (2 .0 ) 87 .0  (14 .8 )
S ad 98 .3  (2 .9 ) 8 4 .7 (1 5 .1 )
Values represent mean percentage (standard deviation). +Only responsive trials 
included in calculations. * bvFTD percent correct > 50%, p<0.05 for all emotions.
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2 .3 .2  Im a g in g  d a ta
2 .3 .2 .1  B v F T D p a tie n ts  versu s h ea lth y  co n tro ls  (Table 2.3)
Anger
As predicted, relative to healthy controls, bvFTD patients showed reduced activity 
in the right inferior frontal gyrus (BA 47; t(36) = -3.78,/?<0.005) while viewing angry 
expressions (Figure 2.3 A). BvFTD patients also demonstrated decreased BOLD signal in 
the left amygdala ( t(36) = -2.11,p < 0 .0 5 ). Consistent with predictions that secondary 
reductions would be observed in temporal-occipital visual areas in bvFTD, reduced 
BOLD signal was observed in the left fusiform gyrus (BA 37; t(36) = -3.18,/?<0.005) 
(Figure 2.3B) and right cuneus (BA 17; t(36) = -3.43,/?<0.005) compared to controls. In 
contrast, increased BOLD signal was observed in bvFTD patients compared to controls in 
the right inferior parietal lobule (BA 39; f(36) = 3.66,/?<0.005) and left posterior 
cingulate cortex (BA 31; t{36) = 3.12,/?<0.005) (Figure 2.3C).
Disgust
Consistent with the role of the insula in the processing of disgusted stimuli and 
the involvement of this region early in the course of bvFTD, patients with bvFTD 
demonstrated decreased BOLD signal in the right (BA 13; t{36) = -3.21,/?<0.005) and 
left insula (BA 13; t(36) = -3.49,/?<0.005) to disgusted facial expressions (Figure 2.4).
As well, patients showed reduced activation in the left lingual gyrus (extending into 
fusiform cortex; BA 18; t{36) = -3.41,/?<0.005) and right middle occipital gyrus (BA 18; 
t(36) = -3.12,/?<0.005) compared to control participants.
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Happy
Relative to healthy controls, bvFTD patients demonstrated decreased BOLD 
signal in the left amygdala (/(36) = -2.31,/?<0.05) (Figure 2.5), yet increased BOLD 
signal in the right inferior parietal lobule (BA 39; t(36) = 3.05,p < 0 .005).
Fear
BvFTD patients demonstrated decreased BOLD signal relative to controls in the 
left medial frontal gyrus (BA 6; 7(36) = -3.25,p < 0 .005), left lingual gyrus (extending into 
fusiform cortex; BA 18; 7(36) = -3.60,p < 0 .005), left middle occipital gyrus (BA 18; 7(36) 
= -3.23,p < 0 .005), and right cuneus (BA 17; 7(36) = -3.25,/K0.005 while viewing fearful 
expressions.
Sad
Compared to healthy controls, bvFTD patients demonstrated decreased BOLD 
signal while viewing sad facial expressions in the left anterior cingulate cortex (BA 6/24; 
7(36) = -4.04,/?<0.005), left lingual gyrus (extending into fusiform cortex) (BA 18; 7(36) 
= -3.08,/?<0.005), right insula (BA 13; 7(36) = -4.03,/?<0.005), right cuneus (BA 17; 
7(36) = -3.45,/?<0.005), left precuneus (BA 7; 7(36) = -3.12,/?<0.005), right superior 




We conducted an additional contrast to further explore the finding that bvFTD 
was associated with increased activity relative to controls in posterior parietal and 
posterior cingulate cortices during angry and happy facial expressions. Recent evidence 
implicates parietal regions in stabilizing goal-relevant stimuli that are not strongly 
represented, perhaps due to reduced afferent input from emotion-related brain regions 
(Amting et al., 2010). Accordingly, we hypothesized that increased activity in this dorsal 
network may reflect increased top-down efforts to enhance representation of faces in the 
ventral visual stream caused by reduced limbic input to this region in bvFTD patients. If 
so, we predicted that bvFTD patients would show augmented posterior parietal and 
posterior cingulate cortex activation during low emotional intensity faces when task 
demands are greatest relative to high emotional intensity faces, compared to controls. To 
test this hypothesis we examined differences between bvFTD patients and controls for 
both high emotional intensity (100%) and low intensity (40%) stimuli across all 
emotional expressions. During high intensity expression processing, bvFTD patients 
showed increased activity only in right inferior parietal lobule (BA 39; t{36) = 3.24, 
/><0.005) relative to controls. Consistent with our hypothesis, during low intensity 
emotional face processing bvFTD patients showed increased activation relative to 
controls in an expanded dorsal network including both right (BA 39; t(36) = 3.84, 
/><0.005) and left inferior parietal lobules (BA 39; /(36) = 3.19,/?<0.005), left posterior 
cingulate cortex (BA 31; /(36) = 3.07,/><0.005) and left precuneus (BA 7; t(36) = 3.03, 
/?<0.005) (Figure 2.6 and Table 2.4).
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Table 2.3. Neural regions demonstrating significant BOLD differences between bvFTD 
patients and healthy controls during emotional face processing
A n a to m ic a l lo ca tio n L /R B A V o lu m e  (m m 3) C o o rd in a tes
*  y z
t  v a lu e
A n g ry  e x p ress io n s
bvFTD < controls 
In fe r io r  fro n ta l g y ru s R 47 189 23 9 -22 -3 .78
A m y g d a la* * L N A 2 1 6 -23 0 -26 -2.11
F u s ifo rm  g y ru s L 37 675 -35 -51 -14 -3 .18
C u n eu s R 17 324 23 -89 8 -3 .43
bvFTD > controls 
P o s te r io r  c in g u la te  co rtex L 31 351 -2 -46 26 3.12
In fe r io r  p a rie ta l lobu le R 39 270 38 -62 32 3 .66
D isg u st  e x p ress io n s
bvFTD < controls 
In su la R 13 432 38 14 7 -3.21
In su la L 13 270 -35 23 4 -3 .49
L in g u a l/fu s ifo rm  g y ru s L 18 324 -2 0 -73 -5 -3.41
M id d le  o cc ip ita l gy ru s R 18 351 23 -89 11 -3 .12
H a p p y  e x p ress io n s
bvFTD < controls 
A m y g d a la* L N A 648 -26 -4 -26 -2.31
bvFTD > controls 
In fe r io r  p a rie ta l lobu le R 39 432 41 -69 38 3.05
F ea r  ex p ress io n s
bvFTD < controls 
M ed ia l fro n ta l g y ru s L 6 270 -2 -4 52 -3 .26
L in g u a l/fu s ifo rm  g y ru s L 18 216 -5 -91 -17 -3 .60
M id d le  o cc ip ita l gy ru s L 18 216 -20 -92 11 -3.23
C u n eu s R 17 432 23 -89 8 -3 .25
S ad  e x p ress io n s
bvFTD < controls 
A n te r io r  c in g u la te  co rtex L 6/24 459 -2 7 51 -4 .04
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L in g u a l/iu s ifo rm  g y ru s L 18 270 -17 73 -5 -3 .08
In su la R 13 243 44 -14 8 -4 .03
C u n eu s R 17 324 23 -89 8 -3 .45
P recu n eu s L 7 324 -8 -81 44 -3 .12
S u p e rio r fro n ta l g y ru s R 9 297 32 49 35 -3 .27
In fe r io r  p a rie ta l lo b u le R 40 297 41 34 34 -3 .46
All regions corrected for whole brain voxel-wise grey matter. Displayed in the table are: hemispheric location (L = 
left; R = right), Broadmann’s area (BA), volume, Montreal Neurological Institute coordinates at the centre o f peak 
activation (x,y,z), and maximum activity (/ value) for each significant cluster. Functional threshold at p<  0.005; p < 
0.05, corrected; *p < 0.05; p < 0.05, small volume corrected; ** p < 0.05; uncorrected.
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bvFTD < Controls, p < 0.005
bvFTD < Controls, p < 0.05 |
bvFTD > Controls, p < 0.005
bvFTD > Controls, p < 0.05 ■
Figure 2.3. During angry expression processing, bvFTD patients demonstrated 
decreased BOLD signal (blue/green) compared to controls in (A) right ventrolateral 
prefrontal cortex and (B) ventral visual stream, specifically left fusiform gyrus. In 
contrast, bvFTD patients showed increased BOLD signal (red/yellow) in (C) right 
inferior parietal lobule and left posterior cingulate cortex. Significant clusters are shown 
at /?<0.005 in yellow and green, and to illustrate the extent of the activations, at /?<0.05 
(uncorrected for multiple comparisons) in red and blue. Statistical maps are corrected for 
voxel-wise grey matter differences.
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bvFTD < Controls, p < 0.005 
bvFTD < Controls, p < 0.05 ■
Figure 2.4. During disgusted expression processing, decreased BOLD signal 
(blue/green) in bilateral insula and right middle occipital gyrus is observed in bvFTD 
patients compared to controls. Significant clusters are shown at p<0.005 in green, and to 
illustrate the extent of the activation, at p<0.05 (uncorrected for multiple comparisons) in 
blue. Statistical map is corrected for voxel-wise grey matter differences.
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bvFTD < Controls, p < 0.005 
bvFTD < Controls, p < 0.05 ■
Figure 2.5. During happy expression processing, decreased BOLD signal (blue/green) in 
the left amygdala was observed in bvFTD patients relative to controls. Significant 
clusters are shown at p<0.005 in green, and at p<0.05 (uncorrected for multiple 
comparisons) in blue to show the full extent of the activation. Statistical map is corrected 
for voxel-wise grey matter differences.
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Table 2.4. Neural regions demonstrating significant BOLD differences between bvFTD 
patients and healthy controls during facial expression processing of specific emotional 
intensities
A n a to m ic a l  lo c a tio n L /R B A V o lu m e  (m m 3)
X
C o o rd in a te s
y z
t  v a lu e
1 0 0 %  in te n s i ty
b v F T D  > co n tro ls  
In fe r io r  p a rie ta l lobu le* R 39 189 38 -62 32 3 .24
4 0 %  in te n s i ty
b v F T D  > co n tro ls  
In fe r io r  p a rie ta l lo b u le R 39 729 47 -65 35 3 .84
In fe rio r  p a rie ta l lo b u le* L 39 54 2 12 46 3 .19
P o s te r io r  c in g u la te  co rtex * L 31 108 -5 -59 26 3 .07
P recu n eu s  * L 7 81 -5 -65 35 3.03
All regions corrected for whole brain voxel-wise grey matter. Intensities for facial expressions are collapsed across 
emotions. Functional threshold at p  < 0.005; p  < 0.05, corrected * p < 0.005; uncorrected.
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bvFTD > Controls, p < 0.005 
bvFTD > Controls, p < 0.05 ■
Figure 2.6. Contrast of low (40%) emotional intensity facial expressions in bvFTD 
patients compared to controls demonstrating increased BOLD signal (red/yellow) in 
bvFTD patients in a dorsal attentional network including bilateral inferior parietal lobule, 
left posterior cingulate cortex, and left precuneus. Significant clusters are shown at 
p<0.005 in yellow, and at p<0.05 (uncorrected for multiple comparisons) in red to 
illustrate the extent of activation. Statistical map is corrected for voxel-wise grey matter 
differences.
2 .3 .2 .2  B vF T D  p a tie n ts  w ith o u t sem a n tic  d e fic its  versu s  bvF T D  p a tie n ts  w ith  sem a n tic  
d e fic its  (Table 2.5)
In order to determine emotion-specific functional differences between bvFTD 
subtypes during facial expression processing we compared bvFTD patients without 
semantic deficits versus bvFTD patients with semantic deficits.
Anger
Relative to bvFTD patients with semantic deficits, bvFTD patients without 
semantic deficits demonstrated decreased BOLD signal in both right (BA 9; t(18) = -3.38, 
p < 0.005) and left superior frontal gyrus (BA 8; f(18) = -3.56,/?<0.005), and right middle 
frontal gyrus (BA 9; /(18) = -3.81,/?<0.005) while viewing angry facial expressions.
Happy
Relative to bvFTD patients with semantic deficits, bvFTD patients without 
semantic deficits demonstrated decreased BOLD signal to happy faces in right medial 
frontal gyrus (BA 10; /(18) = -3.38,/?<0.005), but increased BOLD signal in left 
amygdala (/(18) = 2.65,/?<0.05) (Figure 2.7).
Sad
Relative to bvFTD patients with semantic deficits, bvFTD patients without 
semantic deficits demonstrated decreased BOLD signal in left anterior cingulate cortex 
(BA 24; /(18) = -3.94,p < 0 .005) and left medial frontal gyrus (BA 9; f(18) = -3.38,
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p<0.005), but increased BOLD signal in left amygdala (f(18) = 2.65,/?<0.05) while 
viewing sad facial expressions.
Fear
Relative to bvFTD patients with semantic deficits, bvFTD patients without 
semantic deficits demonstrated decreased BOLD signal to fearful faces in both right (BA 
6; f(18) = -3.45,p<0.005) and left superior frontal gyrus (BA 6; ¿(18) = -3.46,p<0.005), 




No significant BOLD differences were found during disgusted expression 
processing between bvFTD patients with versus without semantic impairments.
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Table 2.5. Neural regions demonstrating significant BOLD differences between bvFTD 
patients without semantic deficits and bvFTD patients with semantic deficits during 
emotional face processing
A n a to m ic a l lo ca tio n  L /R  B A V o lu m e  (m m 3) C o o rd in a tes  
x  y  z
t  v a lu e
A n g r y  ex p ress io n s
bvFTD without semantic deficits < bvFTD with semantic deficits
S u p e rio r  fro n ta l g y ru s  L  8 1269 -17 46 44 -3 .56
S u p e rio r fro n ta l g y ru s  R  9 1242 11 55 42 -3 .38
M id d le  fro n ta l g y ru s  R  9 513 32 46 41 -3.81
H a p p y  e x p ress io n s
bvFTD without semantic deficits < bvFTD with semantic deficits
M e d ia l f ro n ta l g y ru s  R  10 351 20 45 -5 -3 .38
bvFTD without semantic deficits > bvFTD with semantic deficits
A m y g d a la*  L  N A 513 -17 -1 -11 3 .26
S ad  ex p ress io n s
bvFTD without semantic deficits < bvFTD with semantic deficits
A n te rio r  c in g u la te  c o rtex  L  24 324 -2 22 27 -3 .94
M ed ia l fro n ta l g y ru s  L  9 216 -8 47 22 -3 .38
bvFTD without semantic deficits > bvFTD with semantic deficits
A m y g d a la* *  L  N A 54 -20 -1 -15 2 .65
F ea r  e x p ress io n s
bvFTD without semantic deficits < bvFTD with semantic deficits
S u p e rio r fro n ta l gy ru s L  6 837 -23 8 62 -3 .46
S u p e rio r fro n ta l g y ru s  R  6 405 20 11 62 -3 .45
M id d le  fro n ta l g y ru s  L  6 351 -17 -11 67 -3.45
P recu n eu s  L  7 432 -23 -54 55 -3 .28
D isg u st  ex p ress io n s
N o n e
All regions corrected for whole brain voxel-wise grey matter. Functional threshold at/? < 0.005; p < 0.05, corrected; *p 
< 0.05; p  < 0.05, small volume corrected; ** p < 0.05; uncorrected.
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bvFTD (no semantic) < bvFTD (with semantic), p < 0.005 ■
bvFTD (no semantic) > bvFTD (with semantic), p < 0.05 (SVC) ■
Figure 2.7. Contrasting bvFTD patients with and without semantic deficits during 
happy expression processing reveals significantly decreased BOLD signal (blue) in right 
medial frontal gyrus but increased BOLD signal (red) in the left amygdala in bvFTD 
patients without semantic deficits. Identified clusters are significant at p <  0.005 (except 
for the amygdala which is significant at p<0.05, small volume corrected). Statistical map 




The current study used fMRI to delineate the emotion-specific neural correlates of 
implicit facial emotion processing in patients with bvFTD. We found that fMRI was 
sensitive in detecting emotion-specific changes in BOLD signal in bvFTD patients within 
frontotemporal regions previously implicated in the processing of specific emotions in 
healthy controls and affected by bvFTD pathology, even after correcting for measureable 
grey matter loss. Following our predictions, BOLD signal decreases were also observed 
in the ventral visual stream, a region not typically affected by bvFTD pathology, perhaps 
suggesting a functional disconnect between ventral visual cortices and frontal and limbic 
regions. The present results indicate that functional differences between bvFTD subtypes 
(those with and without semantic impairment) can be delineated using fMRI. Finally, 
increased activation was observed in bvFTD patients in a cortical network implicated in 
attentional processes, providing some of the first evidence to suggest that top-down 
compensatory mechanisms are recruited during cognitive processes in bvFTD.
2 .4 .1  F u n ctio n a l n eu ra l c o r re la te s  o f  im p lic it em o tio n a l f a c e  p r o c e s s in g  in bvF T D
Prior studies of the neural correlates of emotion processing in FTD have focused 
exclusively on structural atrophy and found a limited number of associations. For 
example, reduced right inferolateral temporal cortex volume associated with deficits in 
negative emotion recognition (Rosen et al., 2006) and reduced posterior insula volume 
associated with anger recognition difficulties (Omar et al., 2010). In the present study, 
the use of fMRI during emotional stimuli processing demonstrated, for the first time, the
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neural representation of emotional expressions in patients with bvFTD after controlling 
for structural abnormalities.
Considerable evidence suggests that a number of neural regions activated by 
emotional facial expressions are also active when one experiences the expression oneself 
(Carr et al., 2003; Leslie et al., 2004; Preston and de Waal, 2002; Wicker et al., 2003). 
This “mirroring” of another’s emotional expressions is thought to generate internal 
representations of both the motor features as well as other regions relevant to the 
significance of the specific emotion (Budell et al., 2010; Carr et al., 2003). Supporting 
this model, bvFTD patients showed decreased BOLD activation within insular cortex in 
response to disgusted facial expressions, consistent with the known role of this region in 
normal disgust processing (Calder et al., 2007; Phillips et al., 1997; Sprengelmeyer et al., 
1998), and in early bvFTD pathology (Seeley et al., 2008). Insula activation to disgusted 
faces may reflect the awareness of another’s gustatory processes (Jabbi et al., 2007); thus, 
reduced insula activation to disgust likely underlies some patients’ own insensitivity both 
towards this social cue and towards disgusting environmental stimuli (e.g. rotten or raw 
foods; Calder et al., 2007; Ikeda et al., 2002). When viewing angry faces, bvFTD 
patients demonstrated decreases in BOLD activation in ventrolateral prefrontal cortex. 
Previous work has associated ventrolateral prefrontal cortical activation with angry 
expression processing (Blair et al., 1999) and in modulating socially adaptive behaviour 
in response to social cues (Blair and Cipolotti, 2000; Finger et al., 2006; Marsh et al., 
2009). Similarly, ventrolateral prefrontal cortex atrophy has been associated with 
inappropriate social behaviours in patients with FTD (Massimo et al., 2009). BvFTD 
patients showed decreased activation in the amygdala while viewing happy faces,
demonstrating the sensitivity of fMRI in detecting neural dysfunction for an emotion 
frequently correctly recognized by patients with bvFTD (Femandez-Duque and Black, 
2005). Counter to predictions, we did not find significant differences in the amygdala 
during fearful face processing despite the frequent association of this region with fearful 
face processing in healthy adults (Morris et al., 1996; Whalen et al., 1998). In the present 
study, this likely resulted from the lack of significant amygdala activation in the control 
participants during fearful faces. The reason for this lack of response in the controls is 
unclear, as prior studies using similar fearful facial expression stimuli with similar 
presentation parameters have reported increased amygdala activity in control participants 
when viewing fearful faces (Marsh et al., 2008; Morris et al., 1996). Furthermore, gender 
discrimination reaction times were not assessed; however, different reaction times 
between bvFTD patient and controls may potentially influence the BOLD signal as it 
may indicate different lengths of time engaging with the stimuli. Future analyses may 
benefit from including reaction time to further elucidate neural dysfunction during social- 
cognitive tasks in bvFTD.
Past correlations of atrophy patterns with recognition of emotional facial 
expressions have been insensitive in detecting significant differences between frontal- 
dominant and temporal-dominant FTD anatomical subtypes (Omar et al., 2010). We 
examined whether fMRI would be sensitive in delineating functional differences between 
bvFTD subtypes reflecting temporal versus frontal predominant pathologic patterns 
(presence or absence of semantic impairment) (Rosen et al., 2002a; Seeley et al., 2005) 
during facial expression viewing. Across several emotions, bvFTD patients without 
semantic deficits showed reduced activation in regions of prefrontal cortex compared to
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those with semantic deficits. In contrast, bvFTD patients with semantic deficits 
demonstrated reduced activation in the amygdala for happy expressions. The present 
results indicate that fMRI with targeted cognitive tasks can reveal functional 
dissociations between these subtypes, providing support for the power of fMRI to 
delineate neural differences both between bvFTD and controls as well as between bvFTD 
subtypes.
Neuroimaging and lesion studies indicate that regions comprising the distributed 
neural face processing network communicate and influence each other, rather than 
functioning independently. Functional imaging studies in humans have demonstrated 
that ventral visual cortices, specifically lateral fusiform cortex, shows more activation for 
emotional (angry, happy, fearful, sad or disgusted) versus neutral faces (Amting et al., 
2010; Fusar-Poli et al., 2009; Morris et al., 1998; Pessoa and Ungerleider, 2004; 
Vuilleumier et al., 2001), and for higher emotional intensities versus lower (Surguladze et 
al., 2003). Research suggests that projections from the amygdala modulate activity in the 
ventral visual stream, augmenting activation in fusiform cortex for emotionally salient 
stimuli (Amaral et al., 1992; Vuilleumier et al., 2001, 2004). While the amygdala 
responds to crude, low resolution aspects of emotional faces, the fusiform is implicated in 
processing features in higher resolution (Vuilleumier et al., 2003). In addition to 
fusiform cortex, other visual areas modulated by anterior frontal and limbic structures in 
response to emotional facial stimuli include posterior temporal cortex, occipital gyrus, 
cuneus, and lingual gyrus (Pessoa et al., 2002; Vuilleumier et al., 2001, 2004).
Consistent with these models, we found that bvFTD patients demonstrated reduced 
activity in fusiform cortex and other ventral visual regions during the viewing of negative
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emotional expressions (angry, fearful, disgusted, sad). Of interest, this pattern was not 
observed during happy expressions -  the expression usually least affected in bvFTD 
(Femandez-Duque and Black, 2005), despite our finding of reduced amygdala activity 
when viewing this emotion. We suggest that decreased activation in the ventral visual 
stream in bvFTD patients during negative emotional face processing is most likely due to 
reduced afferent inputs from more anterior frontotemporal and limbic regions. This 
hypothesis can be further explored in future studies via a functional connectivity analysis, 
where bvFTD patients would be predicted to demonstrate reduced correlated BOLD 
activation between ventral visual regions (specifically fusiform cortex) and limbic 
structures during facial expression viewing.
2 .4 .2  T op-dow n  co m p en sa to ry  re sp o n se  in bvF T D  a s  a  fu n c tio n  o f  em o tio n a l in ten sity  
The current study provides some of the first evidence that at the neural level, 
patients with bvFTD may augment activity in regions not directly affected by FTD to 
compensate for their emotional impairment. Previous studies have demonstrated that 
emotion-related subcortical activity serves to boost stimulus representation in the ventral 
visual system in a “bottom-up” manner (Amting et al., 2010; Blair and Mitchell, 2009; 
Morris et al., 1998; Pessoa et al., 2002). Face perception tasks limiting ventral visual 
(bottom-up) input have detected increased associated frontoparietal (top-down) activity in 
the “dorsal attention network” (Tomasi and Volkow, 2011), including regions such as 
inferior parietal lobule, posterior cingulate cortex, dorsolateral prefrontal cortex, and 
precuneus (Amting et al., 2010; Kouider et al., 2009; Li et al., 2009). Indeed, a number 
of studies now show that frontoparietal activity increases with heightened demands
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during a variety of cognitive processes including attention, decision-making, or rule- 
learning (Dumontheil et al., 2011; Mitchell, 2011; Mitchell et al., 2007, 2009).
Activation of this dorsal attention network provides important contributions in conditions 
when bottom-up stimulus amplification is reduced during face processing (Amting et al.,
2010), consistent with prior suggestions that attention enhances neural representation in 
category-specific regions (Desimone and Duncan, 1995). In the present study, bvFTD 
patients displayed increased activation compared to controls in a dorsal attentional 
network, including the inferior parietal lobules, posterior cingulate cortex, and precuneus 
for several of the emotional expressions. To further explore the hypothesis that this 
activity reflected top-down compensatory efforts to bolster facial expression processing 
in fusiform cortex in the absence of limbic modulation, we examined whether activity in 
this network was greater for the low emotional intensity compared to high intensity facial 
expressions. In both bvFTD patients and controls, high emotional intensity expressions 
would be expected to generate a greater limbic response compared to low intensity faces, 
leading to a reduced need for top-down compensation during the viewing of high 
intensity faces. Supporting this model, bvFTD patients recruited more of this dorsal 
attentional network when viewing low emotional intensity faces compared to less 
recruitment during high intensity expressions. This result provides the first evidence in 
bvFTD patients of a potential top-down attentional compensatory response during a 
social-cognitive task.
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2 .4 .3  L im ita tio n s
When interpreting fMRI BOLD signal differences in neurodegenerative diseases, 
atrophy is a potential confound. Neural functional abnormalities, incorporating a volume 
correction into functional analyses, have previously been noted in resting state fMRI and 
arterial spin labeling MRI studies in FTD (Du et al., 2006; Zhou et al., 2010) and fMRI 
studies in Alzheimer’s disease (Dickerson et al., 2005). Although voxel-based 
morphometry has demonstrated sensitivity in measuring volume differences during 
varied stages in bvFTD (Rosen et al., 2002a; Seeley et al., 2008; Whitwell et al., 2009), 
we cannot exclude the possibility that despite the atrophy correction, subtle differences in 
regional volumes, rather than neuronal dysfunction in the absence of atrophy, could 
account for the differences in BOLD signal between groups. An alternative route to 
correct for volume differences between groups would be to incorporate cortical 
thicknesses into the fMRI analysis, following the assumption that cortical thickness 
parallels bvFTD pathology; however, this analytical technique would encompass ROI 
fMRI analysis as opposed to whole brain voxel-wise analysis. Another potential 
limitation is the lack of definitive, autopsy confirmation of FTD in this cohort. Despite 
our clinical sample of bvFTD patients meeting revised criteria for bvFTD diagnosis 
(Rascovsky et al., 2010), autopsy confirmation of FTD is still pending, therefore, 
unintentional inclusion of patients with Alzheimer’s disease or other diseases involving 
progressive frontal lobe dysfunction cannot be ruled out. However, as prior studies of 
patients with Alzheimer’s disease have shown increased amygdala responses during 
facial expression processing (Wright et al., 2007), their inclusion would have been
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expected to reduce power in the present study, and thus would be unlikely to account for 
these results.
2.5 Conclusions
In summary, we have demonstrated that fMRI coupled with an emotion 
processing task can demonstrate functional activation abnormalities in bvFTD and 
between bvFTD subtypes. For the first time, we have demonstrated the functional neural 
correlates of deficient emotion processing in patients with FTD. Given the relationship 
between the viewing of emotional expressions and one’s own internal emotional 
experience, this approach offers an exciting means to objectively measure the internal 
emotional experience of patients with FTD. The results also show for the first time 
increased BOLD activation during task performance which may reflect top-down 
attentional compensatory efforts. The demonstration of these functional differences 
following atrophy correction, and comparisons to other voxel-based morphometry 
studies, suggests that measurable functional abnormalities exceed that of measurable 
atrophy and indicate that future use of fMRI combined with symptom-targeting tasks may 
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The objective of this thesis was to apply fMRI to index the emotion-specific 
neural correlates during implicit emotional face processing in bvFTD patients. This 
study reports fMRI to be sensitive in delineating the emotion-specific differences in 
BOLD signal between bvFTD patients and healthy matched controls within 
frontotemporal regions implicated in the healthy processing of facial expressions and 
affected by atrophy in bvFTD, even following a correction for measurable atrophy 
differences. Second, bvFTD was associated with decreased activation in ventral visual 
stream regions known to be involved in general face processing but not commonly 
affected in FTD, likely reflecting reduced afferent input from more anterior 
frontotemporal and limbic regions. Third, fMRI dissociated neural regions demonstrating 
functional differences during facial expression processing between bvFTD subtypes 
(presence or absence of semantic deficits) reflecting frontal versus temporal predominant 
atrophy patterns, demonstrating the greater potential of fMRI to elucidate neural 
abnormalities in FTD compared to previous structural correlation studies. Lastly, the 
results demonstrate increased activation in bvFTD patients in a top-down dorsal 
attentional network, indicating a potential compensatory neural response for impaired 
limbic system functioning. Importantly, as prior studies have demonstrated the similarity 
in neural activation patterns between viewing emotional facial expressions and 
experiencing the emotion oneself, the present results offer for the first time a potential 
objective quantification of the internal emotional experience in bvFTD. In totality, the 
combination of fMRI and social-cognitive targeted tasks may be a promising tool to
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detect early neural dysfunction in bvFTD prior to significant atrophy progression, as well 
as to assess the efficacy of disease altering treatments. Future follow-up studies may 
benefit from scanning patients longitudinally to index the progression of neural 
dysfunction, including non-symptomatic biological family members of bvFTD patients to 
evaluate fMRI’s power to detect neural dysfunction prior to disease symptom onset, and 
including other non-FTD neurodegenerative control groups (e.g. Alzheimer’s disease) to 







1 No neurologic disease or mental health problems. Taking





5 No neurologic disease or mental health problems. Taking
Pantoprazole for blood pressure.
6 Not available.
7 No reports of neurologic disease, mental health problems,
or prescription medications for mood, depression, anxiety, 
insomnia, high blood pressure, or thyroid.
8 Not available.
9 No neurologic disease. Bipolar disorder. Taking epival
(depakote) and indomethacin
10 Not available.
11 No reports of neurologic disease, mental health problems,
or prescription medications for mood, depression, anxiety, 
insomnia, high blood pressure, or thyroid.
12 No reports of neurologic disease, mental health problems,
or prescription medications for mood, depression, anxiety,
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17 No reports of neurologic disease, mental health problems,
18
or prescription medications for mood, depression, anxiety, 
insomnia, high blood pressure, or thyroid.
Not available.
bvFTD (no semantic deficits)
1 Previous pneumonia episode. Previous anxiety, panic
2
attacks, and depression. Possible early diabetes.
No reports of neurologic disease (apart from FTD), mental
3
health problems, or prescription medications for mood, 
depression, anxiety, insomnia, high blood pressure, or 
thyroid.
Substance abuse, starting in 2005.
4 Amyotrophic lateral sclerosis.
5 Not available.
6 Hypertension since 1967. Present anxiety treated with
7
Effexor.
One possible visual hallucination. Diabetes. Reported
8
episodes of passing out for about 5 minutes (no 
abnormality from Holter monitor).
Diabetes mellitus. Vertebral fracture in a fall with spinal
9
fusion in 1977, resultant arthritis in spine, appendicitis with 
subsequent hernia through incision.
Possible mild depression during earlier age.
10 Diabetes. Hypertension. Hypothyroidism.
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11 Diabetes mellitus. Hypertension. Sleep apnea.
12 Hypertension. Gastroesophageal reflux disease. Tinnitus.
Hypercholesterolemia since 2009.






Migraine-type headaches. Peptic ulcer disease. Back pain. 
Seizures. A colloid cyst in the third ventricle of the brain. 
Hypertension. Hypercholesterolemia.
Hiatal hernia type 2 and nerve impingement in neck. 
Diabetes. Hypercholesterolemia.
Hypercoagulability. Diabetes. High mercury and 
aluminum levels underwent chelation therapy. 
Hypertension. Pulmonary embolism (after a long trip). 
History of skull fractures. Questionable depression at age 
20. Second head injury with loss of consciousness at age 
40 but no known hemorrhage or fracture. Developed 
industry-related deafness (progressive).
Hypertension. Hypercholesterolemia. Gastroesophageal 
reflux disease. Osteoarthritis. Chemical exposure to 
muriatic acid in 1996 (caused hospitalization for 6 weeks 




Neuropsychological testing sample sizes
H e a lth y  co n tro ls  b v F T D  w ith o u t SD  b vF T D  w ith  SD
/i 8 m  /8
E d u c a tio n , y ea rs 18 12 8
Illn e ss  d u ra tio n , y ea rs N A 12 8
M M S E 15 12 7
F B I N A 12 8
Im m ed ia te  p ro se  reca ll 15 12 6
D e la y e d  p ro se  reca ll 15 12 6
L e tte r  f lu e n c y 15 12 5
S em an tic  f lu e n c y 15 12 5
O b je c t n am in g 15 10 3
S p o n tan eo u s  c lo c k  d raw in g 15 11 3
C lo ck  c o p y in g 15 11 2
B eck  D ep re ss io n  In v en to ry 15 9 0
T ra ils  A 15 9 5
T ra ils  B 15 6 1
A N A R T 15 9 4
W C S T 15 8 4
S troop  A 15 11 3
S troop  B 14 11 2




MMSE Cognitive impairment screen. Items include: time 
and place orientation, word (ball, flag, tree) and 
sentence repetition, delayed word recall (ball, flag, 
tree), backwards spelling (WORLD), naming 
objects, reading/doing “close your eyes”, folding 
paper/place on floor, write a complete sentence, 
copying pentagons. Max = 30.
FBI Inventory to quantify positive and negative 
behaviour and personality changes. Administered 
to caregivers. Useful adjunct in FTD diagnosis. 
Max = 72; sensitive FTD cutoff = 27.
Immediate prose recall Participants are told a story regarding a fire, and are 
asked to recall the story immediately. Max = 21.
Delayed prose recall Participants are asked to recall the fire story (from 
above) after a delay of twenty minutes. Max = 21.
Letter fluency Participants are given 1 minute (for each letter) to 
name as many words beginning with ‘F’, ‘A’, or 
‘S’. Proper nouns (names, places) are not allowed. 
Total number of words across each category is 
summed.
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Semantic fluency Participants are given 1 minute to name as many 
animals as possible.
Object naming Participants are to name 20 objects that are 
presented to them individually (e.g. plastic banana, 
safety pin). Objects that fail to be named without 
cues are subtracted from the total score. Max = 20.
Spontaneous clock drawing Participants are asked to draw a clock, including all 
numbers, and set clock hands to “ 10 after 11”. 
Drawings are scored based on contour, presence of 
all numbers, and proper hand location. Max =10.
Clock copying Participants shown a clock at 10 after 11 and asked 
to copy the clock. Max score =10.
Beck Depression Inventory Participants probed on feelings of sadness, distress, 
sleep cycles, etc. Higher score means higher 
depression rating. Max = 63.
Trails A Participants draw a line connecting numbers in 
order (1 to 25). Score = number of seconds to 
complete path.
Trails B Participants draw a line connecting number to letter, 
number to letter, in order, until path is complete. 
Score = number of seconds to complete path.






Score = number of errors.
Participants shown 4 cards displaying shapes, which 
may vary in shape, colour, and number of shapes, 
and must correctly match a 5th card to one of the 
originally presented cards. Participants must 
decipher the matching principle (shape, colour, 
number) without any clues. Task consists of six 
principles, where participants must match 10 cards 
per principle to advance to the next principle. Max 
=  6.
Participants read as many words (“red”, “blue”, 
“green”) as possible in 45 seconds.
Participants name the ink colour (“red”, “blue”, 
“green”) of the presented words in 45 seconds.
Participants name the colour (“red”, “blue”,
“green”) of the ink of the words, with the ink 
colours being different than the colour denoted by 
the word, in 45 seconds.
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